title: Drug resistance-related microRNAs in esophageal cancer.
abstract: BACKGROUND
  Drug resistance has been the main obstacle in cancer therapy. A number of drug resistance-related molecules are under investigation but no one agent has already been used in clinical practice. The research on drug resistance-related microRNAs (miRNAs) may eventually lead to improved clinical strategies and outcomes for patients with esophageal cancer (EC).
  
  
  METHODS
  This review summarizes the recent advances in drug resistance-related miRNAs in EC, and also analyzes the clinical and therapeutic applications they provide. The authors envisage future developments in the molecular mechanisms of these miRNAs and their potential applications to cancer treatment.
  
  
  CONCLUSIONS
  Drug resistance-related miRNAs can be used as a useful therapeutic tool for EC. More investigations should be performed to promote the success of therapeutic-clinical use of miRNAs in cancer.
authors: Fourth Military Medical University, Xijing Hospital of Digestive Diseases, State Key Laboratory of Cancer Biology, Xi'an, 710032, Shaanxi Province, China. hlhyhj@126.com
authors: Liu
authors: L
authors: Hong
authors: Yu
authors: Y
authors: Han
authors: Qun
authors: Q
authors: Lu
authors: Hongwei
authors: H
authors: Zhang
authors: Qingchuan
authors: Q
authors: Zhao
authors: Kaichun
authors: K
authors: Wu
authors: Daiming
authors: D
authors: Fan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000502:physiology*; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D035683:MicroRNAs